Hickory Asset Management Inc. Makes New $941,000 Investment in IQVIA Holdings Inc. (NYSE:IQV)

Hickory Asset Management Inc. acquired a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 4,787 shares of the medical research company's stock, valued at approximately $941,000.

Several other hedge funds have also modified their holdings of IQV. Capital Performance Advisors LLP purchased a new position in IQVIA during the third quarter worth approximately $27,000. Synergy Asset Management LLC purchased a new position in shares of IQVIA during the 4th quarter valued at approximately $33,000. Avior Wealth Management LLC grew its stake in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after acquiring an additional 87 shares during the period. Assetmark Inc. increased its holdings in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock worth $54,000 after acquiring an additional 196 shares in the last quarter. Finally, Concord Wealth Partners acquired a new position in IQVIA during the third quarter worth $57,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on IQV. Deutsche Bank Aktiengesellschaft cut their target price on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Barclays decreased their target price on IQVIA from $255.00 to $235.00 and set an "overweight" rating on the stock in a research report on Monday, February 3rd. StockNews.com downgraded IQVIA from a "buy" rating to a "hold" rating in a research note on Thursday, November 28th. BTIG Research cut shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Finally, Robert W. Baird lowered their price target on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 21st. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $251.22.

IQVIA Stock Up 1.8 %

Shares of NYSE IQV traded up $3.39 during midday trading on Wednesday, hitting $196.54. The company's stock had a trading volume of 1,702,945 shares, compared to its average volume of 1,412,729. The business's fifty day simple moving average is $199.95 and its two-hundred day simple moving average is $217.09. The firm has a market capitalization of $34.61 billion, a price-to-earnings ratio of 26.21, a price-to-earnings-growth ratio of 1.98 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.86 EPS for the current year.

Insider Buying and Selling at IQVIA

In other news, Director John G. Danhakl bought 1,275 shares of the firm's stock in a transaction that occurred on Tuesday, December 3rd. The stock was purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the transaction, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.60% of the stock is owned by insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.